Skip to content

HARMONi-GI1: Ivonescimab Improves Survival in Biliary Tract Cancer | ESMO 2026

HARMONi-GI1: Ivonescimab Improves Survival in Biliary Tract Cancer | ESMO 2026

Dr. Vilma Barcia Hospital Universitario La Luz

More on gastrointestinal cancers

Everything on gastrointestinal cancers

FDA NEWS | AZUR 1 Update in Rectal Cancer
Regulatory news. October 19, 2026.
Atezolizumab approved with fluoropyrimidine + oxaliplatin for adjuvant Stage III dMMR Colon Cancer (adults & peds ≥2 yrs).
Regulatory news. FDA. October 12, 2026.
Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis
Publication pick. NEJM. October 9, 2026.
GI oncology: NICHE-2 and STELLAR-303
Dr. Nicholas Hornstein. Expert pick. ESMO 2025.
Day 4 round-up: IMvigor011, DYNAMIC-III, FORTITUDE-101
Dr. Gil Morgan. Daily round-up. ESMO 2025. Day 4.
OncoAlert’s consensus on the PROSPECT trial in rectal cancer
June 9, 2023.

The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.

Email address

Your role

Your country

How we use your details